Juvmo

News

The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.

News

A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.